Keywords
hemofilia
emicizumab
How to Cite
Abstract
We present the case of a 9-year-old boy with Hemophilia A and high titer inhibitors, with post-immunotolerance response criteria (ITI) associated with Emicizumab. This strategy contributed to a better control of bleeding; allowed to intensify the physical rehabilitation regimen, and notably favored their quality of life.
In Ecuador, carrying out immunotolerance entails a series of difficulties: high costs, uninterrupted provision of the factor, formation of a multidisciplinary team, laboratories that are responsible for the titration of inhibitors, or the authorization for the use of drugs that are not in the national regulatory framework.
We must establish the best clinical application profile and the economic impact of these innovative therapies (emicizumab, concizumab, fitusiran); especially in our enviroment, in which accessibility to drugs is complex and optimization of resources is the norm.
References
Alvarez Roman M. Guías Españolas para el manejo de la hemophilia. 2022, 1-190.
Callaghan M, Negrier C, Paz-Priel I, Chang T, Chebon S y col. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137(16):2231-2242.
Carcao M, Escurriola C, Santagostina E, Oldenburg J, Liesner R y col. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25:676-684.
Ellsworth P, Ma A. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology Am Soc Hematol Educ Program. 2021, Dec 10;2021(1):219-225.
Holstein K, Le Quellec S, Klamroth R, Batorova A y col. Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors? Haemophilia. 2022 Mar;28(2):215-222.
Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M y col. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug;26 Suppl 6:1-158.
Young G. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Advances. 2018;2:2780- 2782.
Young G. Management of children with hemophilia A: How emicizumab has changed the landscape. Journal of Thrombosis and Haemostasis. 2021 Jul;19(7):1629-1637.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar